US Patent

US7906489 — 18-membered macrocycles and analogs thereof

Method of Use · Assigned to Optimer Pharmaceuticals LLC · Expires 2027-03-04 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of OPT-80, a potent drug for treating C. difficile infections, which is also known as Dificid.

USPTO Abstract

The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.

Drugs covered by this patent

Dificid (FIDAXOMICIN) · Cubist Pharms Llc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2741`	—	Dificid
`U-319`	—	Dificid

Patent Metadata

Patent number: US7906489
Jurisdiction: US
Classification: Method of Use
Expires: 2027-03-04
Drug substance claim: No
Drug product claim: No
Assignee: Optimer Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.